Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Sep-Oct;46(5):130-5.

[Dry powdered formoterol, twice a day versus aerosolized salbutamol, four times a day, in patients with stable asthma]

[Article in Spanish]
F G Rico-Méndez  1 , G Ochoa, M Rocío Chapela, M Díaz, V Cohen, J Ibarra, E Téllez
Affiliations
  • PMID: 10540564
Clinical Trial

[Dry powdered formoterol, twice a day versus aerosolized salbutamol, four times a day, in patients with stable asthma]

[Article in Spanish]
F G Rico-Méndez et al. Rev Alerg Mex. 1999 Sep-Oct.

Abstract

Material and methods: The objective of this multicenter, open randomized study was to compare the effect of inhaled formoterol (dry powder with ISF system) 12 mcg twice daily versus salbutamol (200 mg qid) in patients with bronchial asthma. A total of 160 patients were evaluated with such diagnosis in four specialized centers; the main variable was the maximal respiratory flow (MEF) assessed prior to drug administration (morning and afternoon). In addition to this, vital capacity (VC), forced respiratory volume over one second (FEV-1), and other safety variables were also determined.

Results: With regard to MEF the administration of formoterol showed better results (P < 0.05) ever since the first month of treatment. The frequency of adverse events was similar between treatment groups; the formoterol group had fewer nightly wake up periods.

Conclusions: That formoterol is a safe, efficacious and long-acting Beta 2 agonist which can be administered twice daily.

PubMed Disclaimer